E
Biodesix, Inc.
BDSX
$1.28
-$0.01-0.78%
E
Sell
2/6/2024Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index, growth index and total return index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index, growth index and total return index.
D
Sell
1/22/2024Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index and total return index.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index and total return index.
E
Sell
1/4/2024Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
D
Sell
12/20/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 12/20/2023 due to an increase in the volatility index and total return index.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 12/20/2023 due to an increase in the volatility index and total return index.
E
Sell
11/30/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/30/2023 due to a decline in the volatility index and total return index.
D
Sell
11/14/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 11/14/2023 due to an increase in the volatility index and solvency index. Debt to equity declined from -3.75 to -18.06, and the quick ratio increased from 0.77 to 0.78.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 11/14/2023 due to an increase in the volatility index and solvency index. Debt to equity declined from -3.75 to -18.06, and the quick ratio increased from 0.77 to 0.78.
E
Sell
11/8/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/8/2023 due to a decline in the volatility index and growth index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/8/2023 due to a decline in the volatility index and growth index.
D
Sell
10/24/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 10/24/2023 due to an increase in the volatility index and total return index.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 10/24/2023 due to an increase in the volatility index and total return index.
E
Sell
10/4/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 10/4/2023 due to a decline in the volatility index.
D
Sell
9/19/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index and total return index.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index and total return index.
E
Sell
8/29/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index.
D
Sell
8/14/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 8/14/2023 due to a substantial increase in the growth index and valuation index. Operating cash flow increased 112.19% from -$7.69M to $937, EBIT increased 33.18% from -$16.35M to -$10.93M, and total revenue increased 31.1% from $9.06M to $11.87M.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 8/14/2023 due to a substantial increase in the growth index and valuation index. Operating cash flow increased 112.19% from -$7.69M to $937, EBIT increased 33.18% from -$16.35M to -$10.93M, and total revenue increased 31.1% from $9.06M to $11.87M.
E
Sell
3/14/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index and growth index. EBIT declined 30.91% from -$10.61M to -$13.89M, operating cash flow declined 15.65% from -$10.33M to -$11.95M, and total revenue declined 13.5% from $11.11M to $9.61M.
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index and growth index. EBIT declined 30.91% from -$10.61M to -$13.89M, operating cash flow declined 15.65% from -$10.33M to -$11.95M, and total revenue declined 13.5% from $11.11M to $9.61M.
D
Sell
2/9/2023Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/7/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from D- on 11/7/2022 due to an increase in the valuation index, growth index and volatility index. Earnings per share increased from -$0.4033 to -$0.3387, EBIT increased 8.74% from -$11.63M to -$10.61M, and total revenue increased 1.43% from $10.95M to $11.11M.
Biodesix, Inc. (BDSX) was upgraded to D from D- on 11/7/2022 due to an increase in the valuation index, growth index and volatility index. Earnings per share increased from -$0.4033 to -$0.3387, EBIT increased 8.74% from -$11.63M to -$10.61M, and total revenue increased 1.43% from $10.95M to $11.11M.
D
Sell
5/12/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 05/12/2022.
Biodesix, Inc. (BDSX) was upgraded to D- from E+ on 05/12/2022.
E
Sell
5/1/2022Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/22/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 4/22/2022 due to an increase in the volatility index.
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 4/22/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
4/18/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index and valuation index.
Biodesix, Inc. (BDSX) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index and valuation index.
D
Sell
3/28/2022Downgrade
Biodesix, Inc. (BDSX) was downgraded to D- from D on 3/28/2022 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 2.22 to 1.26.
Biodesix, Inc. (BDSX) was downgraded to D- from D on 3/28/2022 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 2.22 to 1.26.
D
Sell
3/2/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from D- on 3/2/2022 due to an increase in the valuation index and volatility index.
Biodesix, Inc. (BDSX) was upgraded to D from D- on 3/2/2022 due to an increase in the valuation index and volatility index.
D
Sell
2/11/2022Downgrade
Biodesix, Inc. (BDSX) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
Biodesix, Inc. (BDSX) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
D
Sell
1/26/2022Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from D- on 1/26/2022 due to an increase in the volatility index and valuation index.
Biodesix, Inc. (BDSX) was upgraded to D from D- on 1/26/2022 due to an increase in the volatility index and valuation index.
D
Sell
11/16/2021Downgrade
Biodesix, Inc. (BDSX) was downgraded to D- from D on 11/16/2021 due to a decline in the solvency index, valuation index and total return index. Debt to equity increased from 1.28 to 1.87, and the quick ratio declined from 2.9 to 2.22.
Biodesix, Inc. (BDSX) was downgraded to D- from D on 11/16/2021 due to a decline in the solvency index, valuation index and total return index. Debt to equity increased from 1.28 to 1.87, and the quick ratio declined from 2.9 to 2.22.
D
Sell
11/9/2021Upgraded
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Biodesix, Inc. (BDSX) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/8/2021 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.91 to 1.28, and the quick ratio declined from 4.57 to 2.9.
Biodesix, Inc. (BDSX) was downgraded to E+ from D- on 11/8/2021 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.91 to 1.28, and the quick ratio declined from 4.57 to 2.9.
D
Sell
7/1/2021Upgraded
Biodesix, Inc. (BDSX) was upgraded to D- from E on 7/1/2021 due to a noticeable increase in the solvency index. The quick ratio increased from 2.41 to 4.57.
Biodesix, Inc. (BDSX) was upgraded to D- from E on 7/1/2021 due to a noticeable increase in the solvency index. The quick ratio increased from 2.41 to 4.57.
E
Sell
5/6/2021Downgrade
Biodesix, Inc. (BDSX) was downgraded to E from E+ on 5/6/2021 due to a decline in the volatility index.
Biodesix, Inc. (BDSX) was downgraded to E from E+ on 5/6/2021 due to a decline in the volatility index.
E
Sell
4/1/2021Upgraded
Biodesix, Inc. (BDSX) was upgraded to E+ from E on 4/1/2021 due to an increase in the valuation index.
Biodesix, Inc. (BDSX) was upgraded to E+ from E on 4/1/2021 due to an increase in the valuation index.
E
Sell
3/18/2021Upgraded
Biodesix, Inc. (BDSX) was upgraded to E from E- on 3/18/2021 due to a significant increase in the solvency index, growth index and total return index. The quick ratio increased from 0.21 to 2.41, total revenue increased 194.02% from $9.19M to $27.03M, and earnings per share increased from -$31.9314 to -$0.2444.
Biodesix, Inc. (BDSX) was upgraded to E from E- on 3/18/2021 due to a significant increase in the solvency index, growth index and total return index. The quick ratio increased from 0.21 to 2.41, total revenue increased 194.02% from $9.19M to $27.03M, and earnings per share increased from -$31.9314 to -$0.2444.
E
Sell
1/25/2021None
Biodesix, Inc. (BDSX) was downgraded to E- from U on 01/25/2021.
Biodesix, Inc. (BDSX) was downgraded to E- from U on 01/25/2021.
NASDAQ
04/23/2024 4:00PM Eastern
Quotes delayed
